Filing Flows › Conmed (CNMD) › Q3 2025
Conmed (CNMD) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Conmed (CNMD) reported revenue of $338M for the third quarter 2025 (Q3 2025), +7% from a year earlier and -1% from the quarter before. Operating margin was 3.5%, net earnings $2.9M (0.8% of revenue).
Conmed, Q3 2025: revenue $338M (+7% year over year), operating margin 3.5%, net earnings $2.9M, operating cash flow $53.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $338M | -1% | +7% |
| Gross profit | $166M | -12% | -7% |
| Operating profit | $11.9M | -69% | -82% |
| Net earnings | $2.9M | -87% | -94% |
| Operating cash flow | $53.7M | +84% | +5% |
| Free cash flow | $48.5M | +107% | +1% |
What changed
Revenue was $337.9M in Q3 2025, up 7% year over year and down 1% from the previous quarter. General Surgery was the largest line at 59% of revenue. General Surgery added $13.6M year over year (up 7%), 64% of the total change.
Gross margin was 49.2%, down 7.4 points from a year earlier. Operating profit was $11.9M, a 3.5% margin (down 17.2 points year over year). Operating profit fell $53.8M even though revenue rose $21.2M versus a year earlier, so costs grew faster than sales. Operating expenses grew 36% against revenue growth of 7%. The fastest-growing cost line was SG&A (+41%). Net earnings were $2.9M, down 94% year over year. The effective tax rate was 33.1%.
Operating cash flow was $53.7M (up 5% year over year), 1878% of net earnings. Non-cash charges added back $13.1M of depreciation and amortization and $4.6M of share-based compensation. Working capital and other items added $33.2M. Capital expenditures of $5.2M left free cash flow of $48.5M.
Questions
What was Conmed's revenue in the third quarter 2025?
Conmed (CNMD) reported revenue of $338M for the third quarter 2025 (Q3 2025), +7% from a year earlier and -1% from the quarter before.
Was Conmed profitable in the third quarter 2025?
Operating profit was $11.9M (3.5% of revenue) and net earnings $2.9M.
Source: Conmed 10-Q on SEC EDGAR.